(3-Carboxy-2-propanoyloxypropyl)-trimethylazanium;2-hydroxybutanedioic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: (3-Carboxy-2-propanoyloxypropyl)-trimethylazanium;2-hydroxybutanedioic acid
• 英文别名: (3-carboxy-2-propanoyloxypropyl)-trimethylazanium;2-hydroxybutanedioic acid
• 化学式: C14H26NO9+
• 分子量: 352.36
• InChiKey: OCTBSPFQYSYZAF-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  158
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS
  申请人：University Health Network

  公开号：EP2959292A1

  公开（公告）日：2015-12-30
• METHODS FOR ASSESSING LUNG GRAFTS
  申请人：University Health Network

  公开号：EP2959292B1

  公开（公告）日：2020-09-30
• Methods and Compositions for Assessing Lung Grafts
  申请人：UNIVERSITY HEALTH NETWORK

  公开号：US20150377904A1

  公开（公告）日：2015-12-31

  A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.
• US9835630B2
  申请人：——

  公开号：US9835630B2

  公开（公告）日：2017-12-05
• [EN] METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR L'ÉVALUATION DE GREFFONS DE POUMON
  申请人：UNIV HEALTH NETWORK

  公开号：WO2014127462A1

  公开（公告）日：2014-08-28

  A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.